JP2020513036A5 - - Google Patents

Download PDF

Info

Publication number
JP2020513036A5
JP2020513036A5 JP2020504094A JP2020504094A JP2020513036A5 JP 2020513036 A5 JP2020513036 A5 JP 2020513036A5 JP 2020504094 A JP2020504094 A JP 2020504094A JP 2020504094 A JP2020504094 A JP 2020504094A JP 2020513036 A5 JP2020513036 A5 JP 2020513036A5
Authority
JP
Japan
Prior art keywords
optionally substituted
compound
substituted
alkyl
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020504094A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020513036A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/025991 external-priority patent/WO2018187401A1/en
Publication of JP2020513036A publication Critical patent/JP2020513036A/ja
Publication of JP2020513036A5 publication Critical patent/JP2020513036A5/ja
Priority to JP2023149774A priority Critical patent/JP2023161027A/ja
Pending legal-status Critical Current

Links

JP2020504094A 2017-04-05 2018-04-04 協同的結合に関与する化合物及びその使用 Pending JP2020513036A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023149774A JP2023161027A (ja) 2017-04-05 2023-09-15 協同的結合に関与する化合物及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762481956P 2017-04-05 2017-04-05
US62/481,956 2017-04-05
PCT/US2018/025991 WO2018187401A1 (en) 2017-04-05 2018-04-04 Compounds that participate in cooperative binding and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023149774A Division JP2023161027A (ja) 2017-04-05 2023-09-15 協同的結合に関与する化合物及びその使用

Publications (2)

Publication Number Publication Date
JP2020513036A JP2020513036A (ja) 2020-04-30
JP2020513036A5 true JP2020513036A5 (https=) 2021-05-13

Family

ID=63712657

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020504094A Pending JP2020513036A (ja) 2017-04-05 2018-04-04 協同的結合に関与する化合物及びその使用
JP2023149774A Pending JP2023161027A (ja) 2017-04-05 2023-09-15 協同的結合に関与する化合物及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023149774A Pending JP2023161027A (ja) 2017-04-05 2023-09-15 協同的結合に関与する化合物及びその使用

Country Status (8)

Country Link
US (2) US20200199102A1 (https=)
EP (1) EP3606492A4 (https=)
JP (2) JP2020513036A (https=)
KR (2) KR20200003803A (https=)
CN (1) CN110831632A (https=)
AU (3) AU2018248417A1 (https=)
CA (1) CA3058953A1 (https=)
WO (1) WO2018187401A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9428845B1 (en) 2010-12-28 2016-08-30 Warp Drive Bio, Inc. Identifying new therapeutic agents
KR102455171B1 (ko) 2013-12-18 2022-10-14 더 스크립스 리서치 인스티튜트 변형된 치료제, 스테이플드 펩티드 지질 접합체, 및 이의 조성물
EP3247378B8 (en) 2015-01-09 2023-08-23 Revolution Medicines, Inc. Macrocyclic compounds that participate in cooperative binding and medical uses thereof
EP4302834A3 (en) 2016-07-12 2024-07-17 Revolution Medicines, Inc. 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
JP7240319B2 (ja) 2017-01-23 2023-03-15 レヴォリューション・メディスンズ,インコーポレイテッド アロステリックshp2阻害剤としての二環式化合物
IL269779B2 (en) * 2017-04-05 2026-04-01 Revolution Medicines Inc Methods and reagents for the analysis of protein-protein interfaces
CA3074690A1 (en) 2017-09-07 2019-03-14 Revolution Medicines, Inc. Shp2 inhibitor compositions and methods for treating cancer
TW201930292A (zh) 2017-10-12 2019-08-01 美商銳新醫藥公司 作為變構shp2抑制劑的吡啶、吡嗪和三嗪化合物
JP7361693B2 (ja) 2017-12-15 2023-10-16 レヴォリューション・メディスンズ,インコーポレイテッド アロステリックshp2阻害剤としての多環式化合物
US11691984B2 (en) 2018-10-12 2023-07-04 The Scripps Research Institute Compounds and methods for DCAF-mediated protein degradation
AU2020377925A1 (en) 2019-11-04 2022-05-05 Revolution Medicines, Inc. Ras inhibitors
IL322454A (en) 2019-11-04 2025-09-01 Revolution Medicines Inc ras inhibitors
TW202132316A (zh) 2019-11-04 2021-09-01 美商銳新醫藥公司 Ras抑制劑
MX2022006861A (es) 2019-12-04 2022-07-11 Scripps Research Inst Agonistas del receptor glp2 y metodos de uso.
CA3194067A1 (en) 2020-09-15 2022-03-24 Revolution Medicines, Inc. Ras inhibitors
KR20240017811A (ko) 2021-05-05 2024-02-08 레볼루션 메디슨즈, 인크. 암의 치료를 위한 ras 억제제
KR20240032010A (ko) 2021-06-09 2024-03-08 더 스크립스 리서치 인스티튜트 장기 지속형 이중 gip/glp-1 펩타이드 접합체 및 사용 방법
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
CN115611989B (zh) * 2022-10-09 2023-08-01 武汉理工大学 机械活化淀粉衍生物抑制剂的优化制备方法及应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002503667A (ja) * 1998-02-13 2002-02-05 プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ 新規な二量体化剤、その製造および使用
US7220552B1 (en) * 1999-11-19 2007-05-22 The Board Of Trustees Of The Leland Stanford Junior University Bifunctional molecules and their use in the disruption of protein-protein interactions
DE10146104A1 (de) * 2001-09-19 2003-04-03 Bayer Ag Antibakterielle Markrozyklen
CN1839150A (zh) * 2003-07-17 2006-09-27 麦根克斯有限公司 脂肽抗菌衍生物组合物及其应用方法
US9428845B1 (en) * 2010-12-28 2016-08-30 Warp Drive Bio, Inc. Identifying new therapeutic agents
WO2012174489A2 (en) * 2011-06-15 2012-12-20 The Ohio State University Small molecule composite surfaces as inhibitors of protein-protein interactions
TW201629069A (zh) * 2015-01-09 2016-08-16 霍普驅動生物科技股份有限公司 參與協同結合之化合物及其用途
EP3247378B8 (en) * 2015-01-09 2023-08-23 Revolution Medicines, Inc. Macrocyclic compounds that participate in cooperative binding and medical uses thereof
EP4242304A3 (en) * 2015-10-01 2024-02-07 Revolution Medicines, Inc. Methods and reagents for analyzing protein-protein interfaces

Similar Documents

Publication Publication Date Title
JP2020513036A5 (https=)
KR102820455B1 (ko) Shp2 활성 억제용 화합물의 제조 방법
JP2022093718A5 (https=)
JP5687209B2 (ja) 第2の抗増殖剤と組み合わせて(−)−trans−3−(5,6−ジヒドロ−4H−ピロロ[3,2,1−ij]キノリン−1−イル)−4−(1H−インドール−3−イル)ピロリジン−2,5−ジオンを含有する組成物
JP7328323B2 (ja) SMARCA2/BRM ATPase阻害剤としての尿素化合物及び組成物
JP6896628B2 (ja) 細菌感染症の治療のための抗微生物性ポリミキシン
SG192464A1 (en) 5-phenyl-isoxazole-3-carboxamides modulating hsp90 with antitumoral activities
Türe et al. Design, synthesis and molecular modeling studies on novel moxifloxacin derivatives as potential antibacterial and antituberculosis agents
JP2009541474A (ja) エチオナミド活性の増強効果を有する化合物及びその使用
JP2016527321A (ja) 三環式ベンゾキサボロール化合物及びその使用
JP6515035B2 (ja) マイコバクテリアに対して活性な抗生物質の活性を増強する飽和窒素及びn−アシル化複素環
EA023907B1 (ru) Макроциклические соединения и способы их получения
AU2021239937B2 (en) Oxazolidinone compound and methods of use thereof as an antibacterial agent
WO2016123242A1 (en) (thio)semicarbazone derivatives and their use for treating cancer
Zingle et al. Modifications around the hydroxamic acid chelating group of fosmidomycin, an inhibitor of the metalloenzyme 1-deoxyxylulose 5-phosphate reductoisomerase (DXR)
AU2012257345B2 (en) Substituted indole derivatives for the treatment of immunological disorders
Rabbad et al. Microbes, not humans: exploring the molecular basis of Pseudouridimycin selectivity towards bacterial and not human RNA polymerase
KR20190010631A (ko) Ns5a, ns5b 또는 ns3 억제제를 사용하여 b형 간염 바이러스 감염을 치료하는 방법
WO2013060744A2 (en) Compounds having an ethr inhibiting activity - use of said compounds as drugs - pharmaceutical composition and product containing said compounds
CN111479805B (zh) 治疗性吲唑
JP2019519471A (ja) 環縮合チアゾリノ2−ピリドン類、その製造方法並びに結核の処置及び/又は予防におけるそれらの使用
WO2024035830A1 (en) Solid forms of a cdk inhibitor
JP2007537212A5 (https=)
Liu et al. Identification of novel bacterial RNA polymerase “Switch Region” inhibitors using pharmacophore model based on multi-template and similarity research
JP2020508969A (ja) オーロラaキナーゼ選択的阻害剤